SCHEMBL24916016

SCHEMBL24916016

NC(=O)CNC(=O)[C@@H](N)CSCC(N)=O

nearest known ligand 0.32

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 3/20 0.32
NOS1 P29475 2/20 0.32
NOS3 P29474 1/20 0.32
ARG1 P05089 1/20 0.32
ARG2 P78540 1/20 0.32
METAP1 P53582 1/20 0.31
DPP7 Q9UHL4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4167234 0.78 ALDH1A1 (0.42) ARG1ARG2
SCHEMBL4167228 0.78 ALDH1A1 (0.42) ARG1ARG2
SCHEMBL2633077 0.77 DPP7 (0.36) METAP1DPP7
SCHEMBL2739489 0.77 DPP7 (0.36) METAP1DPP7
SCHEMBL1274426 0.77 CA12 (0.35) METAP1DPP7
SCHEMBL2189880 0.77 CA12 (0.35) METAP1DPP7
SCHEMBL24311695 0.77 METAP1 (0.32) METAP1
SCHEMBL21955443 0.76 ARG1 (0.36) NOS2NOS1NOS3ARG1ARG2
SCHEMBL24013206 0.76 FCER2 (0.40)
SCHEMBL21553675 0.75 MAPT (0.36) METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183292-A1 IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2023-06-15 US disclosed
WO-2023004240-A1 MACROCYLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183292-A1 IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 NOS2 1554/4885NOS1 1721/4885NOS3 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.